Fluent Biosciences Inc.
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Website
- fluentbio.com
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $81,376 |
| FY2023 | $14,147 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
About the company
Fluent Biosciences Inc. is a small disadvantaged biotechnology business located in Watertown, Massachusetts, specializing in advanced biological research technologies and reagent products. The company focuses on developing innovative solutions for single cell RNA sequencing and molecular biology research, with a particular emphasis on their proprietary Pre-templated Instant Partitions (PIPseq) technology. Through federal contract awards, Fluent Biosciences provides specialized biological and reagent products primarily to research-oriented federal agencies, with a strong emphasis on supporting infectious disease and biomedical research initiatives.
The company has received multiple federal contract purchase orders from the National Institute of Allergy and Infectious Diseases (NIAID), consistently delivering biological and reagent products to support infectious disease research programs. These purchase orders, ranging from $11,000 to $29,824, have been firm fixed price contracts for specific reagent products including PIPseq RNA kits, Fluent V nuclei isolation kits, and other proprietary biological reagents. None of the contract awards utilized specific set-aside designations, and all were awarded under purchase order contract types. The contracts consistently target support for infectious disease research, with performance locations specified at Fluent Biosciences' Watertown, Massachusetts facility and completion dates ranging through late 2024.
Fluent Biosciences has secured multiple federal grants from agencies including the National Institute of General Medical Sciences and the National Cancer Institute to develop and commercialize their PIPseq technology. These grants, totaling multiple millions of dollars, focus on advancing single cell RNA sequencing technologies, developing custom assays for circulating tumor DNA monitoring, and creating scalable research tools for high-throughput cellular analysis. Specific grant projects include developing new tools for accessible single cell RNA sequencing, creating custom assays for personalized longitudinal monitoring of circulating tumor DNA, and expanding capabilities for high cell input single cell transcriptomics. The grants support research and commercialization efforts aimed at making advanced molecular biology techniques more accessible, affordable, and scalable for research laboratories.
Quick answers
Is Fluent Biosciences Inc. registered in SAM.gov?
Fluent Biosciences Inc.'s SAM.gov registration expired on April 3, 2025.
What is Fluent Biosciences Inc.'s CAGE code?
Fluent Biosciences Inc.'s CAGE code is 854K0, and its Unique Entity ID (UEI) is DA7UPTVQMG73.
How much has Fluent Biosciences Inc. received in federal contracts?
Federal contracts obligated $95,522 to Fluent Biosciences Inc. in fiscal years 2023 through 2027.
What is Fluent Biosciences Inc.'s most recent federal award?
Fluent Biosciences Inc.'s most recent federal contract award is Consumable biological reagent products (75N93024P01042), from National Institute of Allergy and Infectious Diseases (NIH), on August 23, 2024.
On GovTribe
See Fluent Biosciences Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors